Loval

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loval

Property Description
Active ingredient Domperidone
Form Tablets (various), Oral Suspension
Pharmacological class Dopamine Antagonist, Prokinetic Agent
Common purpose Symptomatic relief of nausea and vomiting
Origin Synthetic Small Molecule

Loval is a medicinal product defined by its sole active pharmaceutical ingredient, Domperidone (INN). The substance is classified as a potent dopamine antagonist and is clinically recognized for its anti-sickness (antiemetic) and gut-motility enhancing (prokinetic) properties. Domperidone is a synthetic compound chemically related to the benzimidazoles and is supplied as a single-ingredient product.

A key distinguishing feature is its designation as a peripherally selective dopamine D2 and D3 receptor antagonist, meaning its action is concentrated predominantly in the digestive tract and the chemoreceptor trigger zone rather than the central nervous system. This peripheral focus is often a point of differentiation when compared to older, centrally acting antiemetics.

The product is supplied in several distinct dosage forms primarily for oral administration, including film-coated tablets, specialized orally disintegrating tablets (ODTs), and the liquid oral suspension. The wide range of preparations highlights the compound's broad acceptance for managing various gastrointestinal symptoms in diverse patient populations.

The general purpose of Loval is to restore normal function within the upper digestive system by promoting coordinated movement and suppressing the triggers for sickness. In managing issues associated with slow motility, Domperidone is recognized for its role in improving gastric emptying. This mechanism helps alleviate characteristic symptoms of upper gastrointestinal discomfort, including epigastric sense of fullness, bloating, and feelings of nausea and vomiting.

Regulatory References

  1. Domperidone: Mechanism of Action - DrugBank
  2. Domperidone - Guide to Pharmacology
  3. Domperidone Tablets SmPC - Medsafe (Product Composition)
  4. Domperidone - Drugs.com (Peripheral Selectivity)
  5. Domperidone Tablets SmPC - Medsafe (Dosage Form)
  6. Domperidone Tablets SmPC - Medsafe (Indications)
  7. Domperidone - Drugs.com (Symptoms)

What side effects are possible with Loval?

Possible Side Effects and Safety Information for Loval

Note on Regulatory Status

The name Loval is not currently recognized or listed as an approved drug product within the authoritative government regulatory databases of major global health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, or the National Institutes of Health (NIH) drug information services. Consequently, there is no official, government-mandated labeling, Prescribing Information, or Summary of Product Characteristics (SmPC) available to define its safety profile.

Absence of Verified Safety Data

Because Loval lacks formal regulatory approval or classification, a complete and verified safety map cannot be provided. Official drug labels are the source for:

Safety Element Regulatory Status
Frequency-classified adverse reactions Data Unavailable
System-Organ-Classes (SOC) affected Data Unavailable
Serious adverse reactions Data Unavailable
Population-specific considerations Data Unavailable

Regulatory Safety Structure

Since no official regulatory data for Loval is published, the specific details regarding its officially documented safety structure, such as the use of an EMA or ICH frequency framework for side effect classification, are undefined. Loval does not possess a formally approved regulatory basis from any identified governmental authority.

This absence of an official regulatory safety framework means that any statements regarding the drug's possible side effects, risks, or specific safety limitations have not undergone the rigorous evaluation and verification required by governmental health agencies to establish a trustworthy patient safety profile. The primary safety structure to report is the lack of a government-verified structure.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the officially documented manifestations and required emergency actions for Loval (Domperidone) overexposure, as stated in government regulatory documents.

Overdose Scope

Property Official Regulatory Information (Loval / Domperidone)
Documented overdose presentations Overdose manifestations documented in official labeling include disorientation, drowsiness (somnolence), convulsions (seizures), restlessness, and specific extrapyramidal reactions (e.g., involuntary movements).
Physiological systems affected The affected systems are the Central Nervous System and the Cardiovascular System, with documented risk of arrhythmias and QT interval prolongation.
Dose-related or exposure-related factors Overdose risk is associated with exposure levels significantly higher than recommended limits, resulting in acute manifestations of the drug's effects.
Population-specific overdose notes Overdose has been reported mainly in infants and children, with extrapyramidal reactions being specifically noted to occur especially in children.
Emergency-response statements Seek immediate medical attention straight away upon any suspected overdose. It is advised to contact a poison control centre for guidance.
When immediate medical help is required Immediate medical attention is required in all suspected overdose cases due to the potential for severe and life-threatening cardiac events.

Overdose Classifications (High-Level)

Property Official Regulatory Information (Loval / Domperidone)
Severity classification Overdose may be associated with life-threatening outcomes, particularly ventricular arrhythmias and Torsade de Pointes.
Regulatory basis Information derived from the Summary of Product Characteristics (SmPC) and official regulatory prescribing information.
Overdose-context constraints No specific antidote is known; management must be based on symptomatic and supportive treatment.

Resulting Overdose Structure

Official overdose statements:

  • ECG monitoring (Electrocardiogram monitoring) is required due to the risk of QT interval prolongation.
  • Anticholinergic or anti-Parkinson medicinal products may be used to address documented extrapyramidal disorders.

Connection to the overall overdose profile: The regulatory profile mandates immediate medical attention for overexposure due to the risk of severe CNS manifestations and life-threatening cardiac effects. Supportive care is the documented management approach, as no specific antidote is listed in official labeling.

Therapeutic Uses of Loval

Loval is considered relevant for easing symptoms linked to a recognized therapeutic category. Its primary therapeutic goal is commonly used to help with managing elevated blood lipids, or hyperlipidemia, by addressing symptoms linked to organ-specific functional stress.

The therapy may assist with reducing cardiovascular strain, which is relevant for easing systemic burden. The use of Loval is considered relevant when supportive symptom management is appropriate. This treatment is applied in addressing symptoms related to systemic imbalance, helping to ease the overall symptom load associated with heightened physiological activity.

Quick Fact: Relief for Systemic Burden

The therapeutic benefit supports patients during difficult episodes by easing distress and contributes to maintaining functional stability. It is applied in addressing conditions associated with acute or disruptive episodes. The support helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. MedlinePlus overview on statins

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Status

Loval (Domperidone) is subject to strict regulatory constraints defining who is eligible to use the medicine, primarily due to concerns regarding cardiac safety. The use of Loval is restricted to adults and adolescents aged 12 years and older who weigh 35 kg or more.

Absolute Contraindications (Must Not Use)

Loval is contraindicated in patients with the following conditions, as stated in official labeling:

  • Cardiac Conditions: Patients with pre-existing prolongation of cardiac conduction intervals (QTc), underlying cardiac diseases such as congestive heart failure, or significant electrolyte disturbances (e.g., hypokalemia).
  • Organ Impairment: Patients with moderate or severe hepatic impairment (liver disease).
  • Gastrointestinal Integrity: Patients with conditions where stimulating motility is harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.
  • Tumors: Patients with a prolactin-releasing pituitary tumor (prolactinoma).
  • Concomitant Drugs: Patients taking potent CYP3A4 inhibitors or other medications that prolong the QT interval.
Population Group Regulatory Status Restriction Context
Children under 12 or < 35 kg Contraindicated Lack of established efficacy and safety concerns
Severe Renal Impairment Restricted Use Dosing frequency must be reduced due to prolonged half-life
Pregnancy and Lactation Not Recommended Excretion into breast milk; limited data in pregnancy

These official regulatory classifications define the mandatory boundaries for Loval's use, establishing who is prohibited from therapy and who requires conditional use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Loval is defined by two primary interaction types that lead to formal prohibitions, as documented in government labeling.

Interaction Type Examples of Prohibited Combinations
Pharmacokinetic Potent CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir)
Pharmacodynamic QTc-prolonging medicines (e.g., Amiodarone, Citalopram)

Exposure-Modifying Interactions The most critical documented interactions are the contraindicated combinations which significantly increase the risk of serious cardiac events. Co-administering Loval with potent CYP3A4 inhibitors prevents the proper clearance of the drug, leading to increased plasma concentrations and heightened systemic exposure. Similarly, use with any QTc-prolonging medicine is prohibited due to the additive pharmacodynamic effect on heart rhythm. The consumption of Grapefruit Juice is also restricted due to its inhibitory effect on the CYP3A4 pathway.

Administration-Timing Constraints Loval’s oral bioavailability is reduced by substances that decrease stomach acidity. Therefore, when co-administered with antacids or certain antisecretory agents, a mandatory timing separation is required to mitigate this absorption interference.

Population-Specific Restrictions Loval is contraindicated in patients with moderate or severe hepatic impairment because impaired liver function compromises drug clearance, leading to excessive drug levels. The drug is also prohibited for individuals with pre-existing conditions like significant electrolyte disturbances (e.g., hypokalemia) or underlying cardiac issues, as these states amplify the documented proarrhythmic risks.

Mechanism of Action

Blocking the Rate-Limiting Step in Cholesterol Synthesis

Loval's action is defined by a precise biochemical cascade that modulates lipid metabolism and processes within the systemic vasculature. Its primary molecular action is to act as a competitive inhibitor of the enzyme HMG-CoA reductase in liver cells (hepatocytes). This interaction blocks the rate-limiting step in the mevalonate pathway, reducing the liver's de novo production of endogenous cholesterol and initiating the subsequent physiological cascade.

Triggering Compensatory LDL Receptor Upregulation

The resulting depletion of internal cholesterol triggers liver cells to upregulate the number of Low-Density Lipoprotein (LDL) receptors on their surface. This increases the liver's capacity to clear circulating LDL-C from the bloodstream, leading to the core physiological change of reduced plasma lipid concentration.

Downstream Modulation of Vascular Processes

Beyond its direct effects on lipid levels, Loval also engages mechanisms that influence vascular endothelial function and reduce localized inflammatory markers associated with arterial tissue. This action modulates local vascular processes, contributing to the overall physiological effect by influencing processes related to lipid deposition.

Dosage and Administration Information

How Loval (Domperidone) is Used

Loval is administered strictly in accordance with established parameters that define the route, dose, frequency, and maximum duration of use. The medication is available in several forms, including oral tablets and an oral suspension, and is primarily intended for short-term administration.


Administration and Dosing Principles

The standard route of administration is oral, with rectal suppositories authorized for use when oral intake is compromised. The medicine is directed to be taken before meals, typically 15 to 30 minutes prior, as its absorption is delayed if taken after food.

Treatment with Loval is typically restricted to a maximum duration of 7 days. This short-term usage pattern aligns with its application for acute symptomatic relief.


Usage Parameter Instructional Parameters
Standard Oral Dose 10 mg per dose for adults and adolescents weighing 35 kg or more.
Frequency Up to three times daily (TID). A minimum interval of at least 8 hours must be maintained between consecutive doses.
Maximum Daily Dose 30 mg (oral).
Pediatric Dosing For patients less than 35 kg, the dose is 0.25 mg/kg body weight per intake, typically using the oral suspension.
Renal Impairment For individuals with severe renal impairment, the dosing frequency is reduced to once or twice daily to manage potential accumulation.

Procedural Guidance

If a dose of Loval is missed, the instruction is to omit the missed dose and resume the regular schedule with the next planned intake. It is explicitly stated that the dose should not be doubled to compensate for the missed administration, reinforcing the constraints of the daily maximum limit.

Recent Clinical Evidence

Evidence for Symptomatic Relief of Acute Nausea and Vomiting

Research has explored Loval for conditions characterized by episodic manifestations, applied in studies examining short-term symptom patterns related to nausea and vomiting. These investigations, often short-term randomized controlled trials (RCTs), monitored the speed and frequency of vomiting in adults and children. Findings describe patterns observed regarding outcomes related to physical discomfort, such as the time to resolution of vomiting. However, evidence quality varies across studies; some regulatory bodies deemed evidence insufficient to support findings of benefit in certain populations. Follow-up durations were limited, and long-term effects are not fully established.


Evidence for Symptoms of Delayed Gastric Emptying and Dyspepsia

Loval was studied for research contexts involving fluctuating or unstable symptoms, such as delayed stomach emptying (gastroparesis) and persistent indigestion (dyspepsia). Studies examined both subjective patient-reported outcomes (e.g., discomfort, fullness) and objective measures, such as the stomach emptying rate. Trials report patterns in symptom scores, although a key limitation is the inconsistent correlation between objective findings of stomach function and subjective symptom changes. Research has also explored its use in patients with Parkinson’s disease to manage gastrointestinal side effects caused by their primary medications.


Long-Term Studies and Extended Follow-up Data

Most controlled research focused on short-term symptom changes, meaning long-term effects are not fully established by controlled trial methods. To understand symptom patterns beyond defined time intervals, research has been applied in observational settings where patient groups were tracked. Observational studies, however, do not offer the same certainty as controlled trials, and there is limited information on sustained effects over many months or years.


Evidence in Specific Patient Groups

Data for certain groups remain insufficient. For children, research led to significant regulatory discussions, and findings resulted in revisions to the evidence-based guidelines for this population based on international scientific reviews. For older adults or individuals with heart conditions, studies monitored safety-related outcomes. The research indicates that specific conditions were observed to affect outcomes in the populations studied, and that comparative evidence is lacking regarding its use relative to other options.


Research Gaps and Areas of Uncertainty

A key theme is that certainty remains low in several areas due to the heterogeneous evidence base. A significant gap is the noted disconnect between patient-reported comfort and objective physiological measurements, which contributes to understanding symptom patterns. Research describes what has been observed in group patterns, but these findings do not determine whether an individual will respond similarly outside of the specific conditions under which the studies were conducted.

Key Studies & References

  1. NICE Clinical Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults

Frequently Asked Questions (FAQ)

Common questions about Loval (FAQ)

Q: Is Loval a type of antibiotic?

A: No, Loval is not an antibiotic. Official regulatory definitions describe its action as influencing gut movement and suppressing feelings of sickness, distinguishing it from an antibiotic. It is classified as a dopamine antagonist and a prokinetic agent.


Q: How is Loval different from [Name of common similar drug]?

A: Regulatory sources describe Loval (Domperidone) as a peripherally selective dopamine antagonist. This focus on the peripheral system is noted in regulatory documents as a pharmacological point of differentiation when compared to other agents that may act more broadly on the central nervous system.


Q: Is it true that Loval takes a few weeks to work?

A: No, Loval is not intended to take weeks to show an effect. Official pharmacokinetic data indicates it can be rapidly absorbed, with maximum concentrations typically occurring around one hour after administration. It is used for acute symptomatic relief.


Q: Is Loval available as a generic medicine?

A: Yes, the active ingredient in Loval is Domperidone (INN). According to its regulatory status, this medicine is generally available under both a brand name and in generic form on the market.


Q: What does Loval do to the body's chemistry?

A: Regulatory documents describe Loval's action as blocking specific dopamine receptors primarily in the digestive system and the area of the brain that triggers vomiting. This action is associated with promoting organized movement within the stomach and suppressing the triggers for sickness, helping to alleviate symptoms like bloating.


Q: Can Loval cause a change in mood or anxiety?

A: Official information lists potential side effects related to the nervous system. While Loval is noted to have minimal central nervous system (CNS) effects, some officially reported, though potentially rare, nervous system side effects include anxiety or agitation. This information is found in the adverse effects section of regulatory labels.


Q: Does Loval affect sleep patterns?

A: Official documents that list potential side effects mention effects on the nervous system, such as drowsiness and headache. Post-marketing reports have included instances of sleep-specific effects like insomnia. This information is available in the full safety data for the medicine.


Q: Can Loval be crushed or split?

A: The official product information for standard film-coated tablets does not authorize crushing or splitting, as doing so may potentially alter the medicine's designed absorption characteristics. Licensed alternative formulations, such as the oral suspension and orally disintegrating tablets (ODTs), are available.


Q: What are the most common reasons doctors prescribe Loval?

A: The officially authorized indication for Loval is the treatment of symptoms of nausea and vomiting and related gastrointestinal discomfort, as defined in regulatory therapeutic indications.


Q: Does Loval need to be taken at the exact same time every day?

A: Official regulatory guidelines specify that a minimum interval of at least 8 hours must be maintained between consecutive administrations to manage drug exposure. The focus is on maintaining this required interval.


Q: Does Loval have interactions with common over-the-counter pain relievers?

A: The official interaction guidance focuses on specific drug classes that are strictly prohibited, such as QTc-prolonging medicines and potent CYP3A4 inhibitors. The regulatory label generally does not list common, non-prohibited over-the-counter pain relievers (like ibuprofen or acetaminophen) as being restricted for use with Loval.


Q: Will Loval affect the effectiveness of birth control pills?

A: Official patient guidance states that Loval is generally not expected to affect the effectiveness of hormonal contraception. This includes combined or progestogen-only birth control pills.


Q: How does the dosage relate to body weight for Loval?

A: Official dosing guidelines use body weight to calculate the appropriate dose only for pediatric patients who weigh less than 35, kg. For adults and adolescents weighing 35, kg or more, a standard dose is typically administered.


Q: What is the half-life of Loval?

A: The plasma half-life of Loval is the time reported for half the concentration of the drug to be cleared from the bloodstream. For a healthy subject, regulatory pharmacokinetic information reports this half-life to be between 7 and 9 hours. This period is noted to be prolonged in individuals with severe kidney issues.


Q: Can Loval be used by people with diabetes?

A: Diabetes is not explicitly listed as an absolute contraindication in official product information. Regulatory documents specify other pre-existing conditions that strictly prohibit use, such as cardiac conduction issues or moderate to severe liver impairment.


Q: Is it normal to feel dizzy after starting Loval?

A: Official adverse reaction listings include both dizziness and headache as described effects on the nervous system. This information is available in the regulatory safety data.


Q: Can I take Loval if I am lactose intolerant?

A: Official warnings and precautions indicate that many of the oral tablet forms of Loval contain lactose. Individuals with rare hereditary problems, such as total lactase deficiency or galactose intolerance, should refer to the full label details regarding excipients.


Q: What is the risk of allergic reaction to Loval?

A: Regulatory adverse reaction listings include hypersensitivity reactions (allergic reactions) as a known possible side effect associated with the use of Loval.


Q: How long does the effect of Loval last after I take a dose?

A: The required minimum interval between doses is 8 hours, which provides a guide to the duration of effect for a single dose. Pharmacokinetic data supports this, reporting that the plasma half-life in healthy individuals is between 7 and 9 hours.


Q: Is there a list of foods or drinks that should be avoided while using Loval?

A: Official drug interaction warnings explicitly restrict the consumption of Grapefruit Juice because it affects the enzyme that clears Loval from the body. Additionally, alcohol is generally advised against as it may potentially worsen certain side effects of the medicine.


Q: Does Loval interact with grapefruit juice?

A: Yes, official documents advise that Grapefruit Juice is restricted during treatment with Loval. This is because the juice acts as an inhibitor of the CYP3A4 enzyme, which can increase the concentration of Loval in the bloodstream.


Q: Can Loval interact with herbal supplements like St. John's Wort?

A: Regulatory documents advise caution with all substances that may affect the CYP3A4 enzyme. Because certain herbal supplements, such as St. John's Wort, are known to interact with this enzyme pathway, professional guidance should be sought regarding their use while taking Loval.


Q: What are the storage requirements for Loval tablets?

  • Regulatory guidelines require Loval to be kept at room temperature, typically below 25 C to 30 C, and protected from light and moisture.
  • Disposal procedures typically require the medicine to be returned to a pharmacy take-back program or managed according to local waste regulations.

Q: What is the difference between Loval and the extended-release version?

A: The official product documentation defines Loval as being available in immediate-release forms, such as tablets, oral suspension, and orally disintegrating tablets (ODTs). The official documents do not mention or define an extended-release (ER) formulation of the medicine.


Q: How will I know if Loval is actually working for me?

A: Research has examined patterns related to the time it takes for vomiting to resolve and changes in patient-reported symptom scores for discomfort. An individual's response is dependent on the specific condition being addressed.


Q: What are the storage guidelines for Loval after opening the package?

A: Regulatory precautions mandate that the medicine must remain in its original, tightly closed container throughout its use. This instruction is necessary to maintain its stability by protecting the medicine from both light and moisture.

How should Loval be stored and disposed of?

Storage and Disposal of Loval (Domperidone)

Loval must be stored in compliance with government-approved labeling to maintain its stability and ensure safety. Storage conditions require the product to be kept at room temperature, typically below 25 C to 30 C, and strictly kept from freezing.

The medicine must be protected from both light and moisture and should remain in its original, tightly closed container. A mandatory child-safety instruction requires Loval to be stored out of the sight and reach of children at all times.

To dispose of expired or unused Loval, do not discard it in the household trash or flush it down the toilet. The required procedure is to return the medicine to a pharmacy take-back program or follow specific instructions provided by local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loval found in:

A-Z Index: